Oxford-Harrington Rare Disease Scholar Award

Oxford-Harrington Rare Disease Scholar Award is sponsored by Oxford-Harrington Rare Disease Centre (OHC). This award accelerates promising therapeutics discoveries from academic labs into clinical practice, including small molecule platforms.

Drug Discovery and Developing Funding for Physician Scientists and Basic Research for Medicine | Oxford-Harrington Rare Disease Scholar Award | Harrington Discovery Institute at University Hospitals 2027 Scholar-Innovator and ADDF-Harrington Oxford-Harrington Rare Disease Scholar Award The Oxford-Harrington Rare Disease Scholar Award advances promising discoveries from academic labs to move them into clinical practice.

The award combines funding and expert therapeutics development support to help researchers in the UK, US, or Canada to accelerate preclinical projects towards treatments for patients. The grant is administered by the Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio.

Harrington Discovery Institute’s UK granting organization is Fund for Cures UK, Ltd. Call Opens for Applications Application Submission Deadline Finalists Contacted for Due Diligence Review Discover how we're bringing hope to patients with rare diseases through groundbreaking research and drug development. Download our brochure to explore our mission and impact.

Specifically, the award includes: Guaranteed grant award of USD$100,000 ($50,000 for year one and $50,000 for year two) for US- and Canada-based awardees and £100,000 (£50,000 for year one and £50,000 for year two) for UK-based awardees One year of therapeutics development support and project management with potential to renew for a second year based on milestones met Access to core facilities and infrastructure including oligonucleotide synthesis and screening, small molecule and protein platforms, cell and gene therapy facilities Opportunity to compete for acceleration funds up to USD$300,000 / £250,000 Opportunity to qualify for investment funds up to USD$1,000,000 according to project requirements Invitation to present at a Harrington Discovery Institute or Oxford-Harrington Center Scientific Symposium *Advisors with Harrington’s Therapeutics Development Center have capabilities in biology/biophysiology, commercial and business development, formulation, medicinal chemistry, pharmacology, pre-clinical and clinical planning, and regulatory and translational.

The advisors have previously held leadership positions at companies such as Merck, Bristol Myers Squibb, Schering-Plough, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, and Allergan.

MD or PhD (or equivalent) researchers in the UK, US, and Canada operating their own independent lab Faculty position at an accredited academic medical center, university or research institution in the UK, US, or Canada, and conduct the majority of their research at that institution A project must have a single Principal Investigator (PI), who is responsible for project oversight and financial management.

The PI may engage collaborators, core labs, or commercial Contract Research Organizations (CROs) to execute any portion of the project. Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects. We welcome and encourage multiple proposals from each institution.

Late submissions will not be accepted for any reason, other than issues with the Harrington Discovery Institute’s submission system. Proposals received after the deadline will not be reviewed. The Oxford-Harrington Rare Disease Scholar Award seeks novel approaches to treat rare diseases.

Proposals of interest include discoveries demonstrating rigorous science, innovation, and potential for clinical impact. Projects with novel, validated targets are of particular interest. The current focus areas of the OHC are neurological disorders, developmental disorders, and rare cancers, but we welcome applications directed to other rare, genetic indications with a high unmet need.

Key considerations also include: Novel approaches to treat rare diseases (Either European or US definition of a rare disease can be applied. Ultra-rare diseases will also be considered).

Potential to be developed into a commercial program Strong intellectual property (IP) or protection strategy Therapeutic programs with clear potential for rapid and safe clinical translation and advancement toward patients Later-stage pre-clinical applications built on well-validated or clinically-validated technologies Rare disease as a mechanism to validate new delivery or platform therapeutic technologies Rare-to-common therapeutics programs that could have utility in both rare and large patient populations Other rare genetic diseases Dee and Jimmy Haslam Make $12.

5 Million Transformational Investment in Blood Cancer Research and Treatments at University Hospitals Benefiting patients worldwide, funding accelerates chronic lymphocytic leukemia research and rare cancer drug development through the Oxford-Harrington Rare Disease Centre and UH Seidman Cancer Center Breaking Into the Brain: Overcoming Barriers to Understand Autism and Brain Tumors In a new episode of the podcast, , welcomes , and , for a conversation on how immune biology is transforming the field of neuroscience and accelerating the path from discovery to patient care.

Dr. Anderson, Investigator at Harrington Discovery Institute and Co-Director of the —a partnership between the University of Oxford and the Harrington Discovery Institute at University Hospitals—brings...

Continue Reading Oxford-Harrington Rare Disease Centre Bio Tech Profile Feature in PharmaSource Oxford-Harrington Rare Disease Centre operates a transatlantic model that embeds industry expertise directly into academic rare disease programs. $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034 Continue Reading